Viemed Healthcare, Inc.

Health Care
Misc Health and Biotechnology Services
www.viemed.com

Earnings Score
Moat Score
Safety Score

Market Cap $334.49M
PE 32
Debt $4.46M
Cash $11.35M
EV $327.60M
FCF $3.51M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$10.43M
EBIT	$16.52M
ROE	8%
ROA	10%
FCF	$3.51M
Equity	$126.80M
Growth Stability	38%
PE	32.08
PEG	-1.96
PB	2.64
P/FCF	95.24
P/S	1.56
Price/Cash	0.03
Debt/Equity	0.04
Debt/FCF	1.27
Net Margins	4%
Gross Margins	60%
Op. Margins	8%
Earnings CAGR	-9%
Sales Growth YoY	17%
Sales Growth QoQ	6%
Sales CAGR	19%
FCF CAGR	-4%
Equity CAGR	27%
Earnings Stability	-0.34
Earnings Growth YoY	33%
Earnings Growth QoQ	164%

Earnings CAGR 5Y	-16%
Sales CAGR 5Y	18%
FCF CAGR 5Y	-3%
Equity CAGR 5Y	18%
Earnings CAGR 3Y	26%
Sales CAGR 3Y	26%
FCF CAGR 3Y	113%
Equity CAGR 3Y	12%
Market Cap	$334.49M
Revenue	$214.30M
Assets	$169.53M
Total Debt	$4.46M
Cash	$11.35M
Shares Outstanding	38.8M
EV	327.6M
Earnings Score	6%
Moat Score	84%
Safety Score	68%
Final Score	53%
Working Capital	11.25M
Current Ratio	1.31
Gross Profit	$129.18M
Shares Growth 3y	-0%
Equity Growth QoQ	5%
Equity Growth YoY	17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Viemed Healthcare Inc is a provider of equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services to neuromuscular patients.

SEC Filings

Direct access to Viemed Healthcare, Inc. (VMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Viemed Healthcare, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Viemed Healthcare, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -9%

Stability -34%

loading chart...

Viemed Healthcare, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Viemed Healthcare, Inc..

Years

Calculation mode

= $27M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$3.5M	$3.4M	$3.3M	$3.1M	$3M	$2.9M	$2.8M	$2.7M	$2.6M	$2.5M	$2.4M	$24M
DCF		$3.1M	$2.7M	$2.4M	$2.1M	$1.8M	$1.6M	$1.4M	$1.2M	$1.1M	$928K	$9.3M
Value	$27M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	15%	11%	24%	8%	4%	6%	4%
ROA	-	11%	24%	11%	8%	9%	10%
ROE	-	20%	39%	10%	6%	9%	8%

Bad Net Margins (4.25%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	1.64	0.35	2.1	0	0.37	1.27
Debt over Equity	0	0.21	0.09	0.06	0	0.06	0.04
Growth Stability	-	-	-	55%	38%	66%	38%

Good Debt/FCF ratio (1.27)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.04)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (38%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	24%	64%	-11%	19%	32%	18%
Earnings YoY growth	-	-10%	270%	-71%	-32%	65%	-16%
Equity YoY growth	-	25%	87%	16%	2%	17%	18%
FCF YoY growth	-	-65%	287%	-88%	76%	294%	-3%